Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference 02/01/26
Welcome to Cardiology Today â Recorded February 01, 2026. This episode summarizes 5 key cardiology studies on topics like warm ischemic time and chronic antibody-mediated rejection. Key takeaway: Chlorthalidone vs Hydrochlorothiazide: No C. V. Risk Difference.
Article Links:
Article 1: Barriers and opportunities in donation after circulatory death heart transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. (Transplantation)
Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. (Journal of the American Heart Association)
Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve. (Journal of the American Heart Association)
Article 5: Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/chlorthalidone-vs-hydrochlorothiazide-no-c-v-risk-difference-02-01-26/
đ Featured Articles
Article 1: Barriers and opportunities in donation after circulatory death heart transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40480320
Summary: Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.
Article 2: Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering.
Journal: Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41063352
Summary: This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.
Article 3: Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614331
Summary: This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol’s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.
Article 4: Pacemaker Implantation Rates With the Self-Expandable Navitor Valve.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614325
Summary: This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165 Evolut patients. The analysis focused on patients without preexisting permanent pacemaker implantation or high-risk electrocardiogram findings. The study provides comparative data on post-transcatheter aortic valve replacement cardiac rhythm management.
Article 5: Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41614323
Summary: The intent-to-treat analysis of the Diuretic Comparison Project (D. C. P.) found no difference in the risk of nonfatal cardiovascular disease or noncancer-related death between chlorthalidone and hydrochlorothiazide. The hazard ratio was 1.04 with a 95 percent confidence interval of 0.94 to 1.16. The current study performed a per-protocol analysis to estimate the effect of chlorthalidone at 12 point 5 or 25 milligrams daily compared with hydrochlorothiazide at 25 or 50 milligrams daily. This analysis examined the comparative effectiveness of these diuretics in preventing major cardiovascular disease or noncancer death.
đ Transcript
Today’s date is February 01, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Barriers and opportunities in donation after circulatory death heart transplantation. Heart utilization from donation after circulatory death (DCD) donors remains highly variable across the United States, which results in missed transplantation opportunities. This national registry analysis investigated donor characteristics, including age and warm ischemic time, in donation after circulatory death cases. The study identified these factors as relevant in the assessment of potential heart donors. Findings suggest better understanding of these variables could improve organ utilization rates.
Article number two. Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. This study found peritubular capillary multilayering (PTCML) is an ultrastructural feature of chronic antibody-mediated rejection (AMR) in 2541 kidney samples. Epidemiological modeling demonstrated that younger recipients, living donation, early chronic antibody-mediated rejection, and pulse corticosteroid rejection treatment were associated factors. Later presentation and higher donor-specific antibodies also showed an association with chronic antibody-mediated rejection. The data thus clarifies diagnostic relationships for this condition.
Article number three. Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. This multicenter cohort study compared the real-world effectiveness of nebivolol, a third-generation beta blocker, against other beta blockers for hypertension management. The study determined nebivolol’s impact on blood pressure and heart rate control. It also clarified associated clinical outcomes in patients with hypertension. The data contributes to understanding optimal beta blocker selection in clinical practice.
Article number four. Pacemaker Implantation Rates With the Self-Expandable Navitor Valve. This study compared 30-day permanent pacemaker implantation (PPI) rates between transcatheter aortic valve replacement (TAVR) patients receiving the self-expandable Navitor system and those receiving the Evolut system. The comparison involved 148 Navitor patients and 165 Evolut patients. The analysis focused on patients without preexisting permanent pacemaker implantation or high-risk electrocardiogram findings. The study provides comparative data on post-transcatheter aortic valve replacement cardiac rhythm management.
Article number five. Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project. The intent-to-treat analysis of the Diuretic Comparison Project (D. C. P.) found no difference in the risk of nonfatal cardiovascular disease or noncancer-related death between chlorthalidone and hydrochlorothiazide. The hazard ratio was 1.04 with a 95 percent confidence interval of 0.94 to 1.16. The current study performed a per-protocol analysis to estimate the effect of chlorthalidone at 12 point 5 or 25 milligrams daily compared with hydrochlorothiazide at 25 or 50 milligrams daily. This analysis examined the comparative effectiveness of these diuretics in preventing major cardiovascular disease or noncancer death.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
warm ischemic time, chronic antibody-mediated rejection, kidney transplantation, self-expandable valve, donor characteristics, epidemiological modeling, chlorthalidone, cardiovascular event prevention, donation after circulatory death, beta blockers, transcatheter aortic valve replacement, diuretic, heart rate control, heart transplantation, donor-specific antibodies, hypertension, Evolut valve, Navitor valve, blood pressure control, hazard ratio, peritubular capillary multilayering, hydrochlorothiazide, nebivolol, permanent pacemaker implantation, organ utilization.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow